Fusion Antibodies plc (AIM:FAB)

London flag London · Delayed Price · Currency is GBP · Price in GBX
15.50
0.00 (0.00%)
Feb 12, 2026, 4:24 PM GMT
Market Cap19.38M +149.3%
Revenue (ttm)1.60M -11.4%
Net Income-1.47M
EPS-0.01
Shares Out125.02M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume119,723
Average Volume535,059
Open15.00
Previous Close15.50
Day's Range15.00 - 16.00
52-Week Range5.60 - 21.00
Beta1.25
RSI57.90
Earnings DateFeb 24, 2026

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceu... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 24
Stock Exchange London Stock Exchange AIM
Ticker Symbol FAB
Full Company Profile

Financial Performance

In fiscal year 2025, Fusion Antibodies's revenue was 1.97 million, an increase of 72.98% compared to the previous year's 1.14 million. Losses were -1.71 million, -23.05% less than in 2024.

Financial Statements